SINGAPORE, Dec. 1, 2022 /PRNewswire/ — MGI Tech Co. Ltd. (MGI), an organization dedicated to constructing core instruments and know-how to steer life science, will be part of world and Asian most cancers professionals at the ESMO Asia Congress 2022 going down 2-4 December in Singapore. In addition, MGI will introduce a free trial marketing campaign on its newest sequencer DNBSEQ-G99* for early customers in APAC at the occasion (extra particulars could be discovered right here).
At ESMO, MGI units to showcase its MGISP-100 Automated Sample Preparation System and DNBSEQ-G99* Genetic Sequencer at Booth C209. Suitable for small and medium-sized analysis laboratories corresponding to in hospitals, MGISP-100 offers an automatic library bundle for the preferred purposes corresponding to breast most cancers, lung most cancers and extra.
Meanwhile, as one of many quickest sequencers* amongst medium-to-low throughput sequencers globally, DNBSEQ-G99* was developed based mostly on MGI’s proprietary DNBSEQ™ know-how and additional enabled by improvements in biochemistry, optics, fluidics, temperature management, and different core programs. It is very relevant for focused oncology panel sequencing, oncology methylation sequencing, small whole-genome sequencing and extra. DNBSEQ-G99* shall be out there in Singapore beginning early 2023.
To enable clients to expertise the fast and high-quality knowledge output of the DNBSEQ-G99*, MGI is providing free trials for early customers in APAC from now till 31 January 2023. Each buyer may have the prospect to get pleasure from as much as 96 Gb knowledge without cost. All events are welcome to go to Booth C209 for extra particulars and to satisfy DNBSEQ-G99* up shut.
“We are excited to showcase our latest achievements and connect with our customers and partners at ESMO Asia Congress 2022,” Dr. Roy Tan, General Manager of MGI Asia Pacific. “MGI is dedicated to empowering our customers in their scientific discovery and enable clinical applications – not only in the field of oncology, but also in drug discovery, precision medicine, precision prevention, and treatment monitoring in Singapore and beyond.”
Earlier in June, MGI shaped an official partnership with MiRXES, a Singapore-headquartered biotechnology firm, to construct an ultra-high-throughput, high-resolution spatial genomics pipeline in Singapore. The collaboration combines the end-to-end RNA translational analysis and region-leading molecular diagnostics improvement capabilities at MiRXES, with the transformational Stereo-seq know-how from BGI-Research, and MGI’s main DNBSEQ-T10×4RS* sequencing system.
The cutting-edge DNBSEQ-T10×4RS* sequencing platform (T10), one of many world’s largest and highest throughput subsequent era sequencers, was unveiled in late November among the many presence of distinguished company together with Dr. Wang Jian, Chairman of MGI. The T10, housed at MiRXES’s purpose-built multi-omics laboratory at Singapore’s Biopolis, is the primary of its sort put in and operationalized in APAC, exterior of China. Through this new system, MGI seems to broaden entry to genomics and scale its optimistic influence throughout Singapore and the area.
In line with its dedication to Singapore’s healthcare improvement, MGI may also take part in The Singapore Healthcare AI Datathon and Expo, co-organized by the National University of Singapore (NUS), National University Health System (NUHS) and MIT Critical Data, as a Gold Sponsor. MGI will host a workshop on 1 December masking MGI’s world adoptions, instruments, and cutting-edge analysis tasks. Moreover, MGI’s know-how and merchandise, together with the ultra-high-throughput sequencer DNBSEQ-T7*, shall be exhibited on 2 December. Further particulars and registration for the workshop could be discovered right here.
About MGI
MGI Tech Co. Ltd. (MGI), headquartered in Shenzhen, is dedicated to constructing core instruments and know-how to steer life science by means of clever innovation. Based on its proprietary know-how, MGI focuses on analysis & improvement, manufacturing and gross sales of sequencing devices, reagents, and associated merchandise to help life science analysis, agriculture, precision medication and healthcare. MGI is a number one producer of scientific high-throughput gene sequencers*, and its multi-omics platforms embrace genetic sequencing*, medical imaging, and laboratory automation. MGI’s mission is to develop and promote superior life science instruments for future healthcare. For extra info, please go to MGI web site or join with us on Twitter, LinkedIn or YouTube.
*For StandardMPS and CoolMPS: Unless in any other case knowledgeable, StandardMPS and CoolMPS sequencing reagents, and sequencers to be used with such reagents should not out there in Germany, Spain, UK, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria, and Romania. Unless in any other case knowledgeable, StandardMPS sequencing reagents, and sequencers to be used with such reagents should not out there in Hong Kong. No buy orders for StandardMPS merchandise shall be accepted in the USA till after January 1, 2023.
SOURCE MGI Tech Co., Ltd.
MGI Cements Its Presence and Contribution in Singapore’s Genomics Landscape at ESMO Asia Congress 2022
MGI Cements Its Presence and Contribution in Singapore’s Genomics Landscape at ESMO Asia Congress 2022
info with out going by means of us first, so we are able to present you the newest and best information with out costing you a dime. The two of you might study the specifics of the information collectively, providing you with a leg up. We’ll get to the subsequent step when a bit time has gone.
Our purpose is to maintain you recent on all the latest information from across the globe by posting related articles on our web site, so that you could be all the time be one step forward. In this fashion, you may by no means fall behind the newest developments in that information.
MGI Cements Its Presence and Contribution in Singapore’s Genomics Landscape at ESMO Asia Congress 2022